BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Icotinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Icotinib\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07458919-2011@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20301030
DTEND;VALUE=DATE:20301031
SUMMARY:Icotinib: Phase 1 readout est. (NCT07458919)
DESCRIPTION:Icotinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Therap
 y for Advanced NSCLC With EGFR 19delins Mutation\nEstimated primary comple
 tion: 30 October 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/icotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07458919
URL:https://assetmemo.bio/drug/icotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955325-2011@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Icotinib: Phase 3 readout est. (NCT06955325)
DESCRIPTION:Icotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Umbrel
 la Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB 
 NSCLC: Focus on Driver Mutations\nEstimated primary completion: December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/icotinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06955325
URL:https://assetmemo.bio/drug/icotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
